Gambaran Umum
Mereo BioPharma Group plc, based in the United Kingdom, operates within the biopharmaceutical sector, focusing primarily on developing and commercializing innovative therapies for rare diseases. The company has a portfolio concentrating on endocrinology, oncology, and rare genetic diseases. One of their key projects includes BPS-804 (setrusumab), a treatment designed for osteogenesis imperfecta, a rare bone disorder. Mereo BioPharma also works on advancing treatments like acumapimod, aimed at addressing acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and alvelestat for alpha-1 antitrypsin deficiency, a genetic disorder that affects the lungs and liver. Their strategic approach combines in-licensing and acquiring under-prioritized programs from larger pharmaceutical companies to manage and propel these products through advanced clinical development stages.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah 0.50 MM.
- Nilai operating income untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah -44.62 MM.
- Nilai net income untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah -49.55 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 0.50 | -44.62 | -49.55 |
2025-03-31 | -47.31 | -47.19 | |
2024-12-31 | -45.72 | -43.25 | |
2024-09-30 | 1.00 | -38.07 | -45.32 |
2024-06-30 | 1.00 | -37.90 | -36.85 |
2024-03-31 | 10.00 | -25.65 | -26.34 |
2023-12-31 | 10.00 | -27.14 | -29.47 |
2023-09-30 | 9.00 | -34.28 | -30.79 |
2023-06-30 | 9.00 | -36.08 | -31.70 |
2023-03-31 | -50.12 | -42.45 | |
2022-12-31 | -52.70 | -42.22 | |
2022-09-30 | 0.00 | -50.05 | -31.43 |
2022-06-30 | 0.00 | -42.54 | -18.52 |
2022-03-31 | 18.23 | -31.74 | -2.90 |
2021-12-31 | 36.46 | -20.94 | 12.72 |
2021-09-30 | 36.46 | -21.01 | -7.10 |
2021-06-30 | 36.46 | -21.08 | -26.92 |
2021-03-31 | 18.23 | -29.33 | -95.27 |
2020-12-31 | -37.57 | -163.63 | |
2020-09-30 | -37.29 | -153.43 | |
2020-06-30 |
Laporan Laba Rugi: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | -0.31 | -0.31 |
2024-12-31 | -0.29 | |
2024-09-30 | -0.31 | -0.31 |
2024-06-30 | -0.26 | -0.26 |
2024-03-31 | -0.19 | -0.19 |
2023-12-31 | -0.22 | |
2023-09-30 | -0.24 | -0.25 |
2023-06-30 | -0.25 | -0.27 |
2023-03-31 | -0.35 | -0.35 |
2022-12-31 | -0.35 | |
2022-09-30 | -0.27 | -0.37 |
2022-06-30 | -0.16 | -0.36 |
2022-03-31 | -0.03 | -0.30 |
2021-12-31 | 0.12 | -0.23 |
2021-09-30 | -0.07 | -0.32 |
2021-06-30 | -0.26 | -0.39 |
2021-03-31 | -1.10 | -1.18 |
2020-12-31 | -2.41 | -2.40 |
2020-09-30 | -3.41 | -3.39 |
2020-06-30 | -6.43 | -6.38 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah -32.92 MM.
- Nilai cash from investing activities untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah -0.32 MM.
- Nilai kas dari aktivitas pendanaan untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) per 2025 Jun 30 adalah -0.35 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -32.92 | -0.32 | -0.35 |
2025-03-31 | -33.17 | -0.32 | 46.57 |
2024-12-31 | -32.83 | -0.70 | 46.15 |
2024-09-30 | -30.20 | -0.70 | 46.19 |
2024-06-30 | -20.02 | -0.70 | 54.69 |
2024-03-31 | -19.88 | -0.70 | 7.97 |
2023-12-31 | -21.13 | -0.42 | 7.97 |
2023-09-30 | -28.28 | 0.03 | 8.24 |
2023-06-30 | -41.92 | 0.33 | 0.64 |
2023-03-31 | -46.44 | 0.97 | 0.38 |
2022-12-31 | -48.82 | 1.99 | 0.20 |
2022-09-30 | -43.32 | 1.30 | -0.26 |
2022-06-30 | -33.95 | 0.55 | -0.65 |
2022-03-31 | -19.59 | 0.07 | 38.50 |
2021-12-31 | -5.24 | -0.42 | 77.65 |
2021-09-30 | -6.26 | -0.32 | 70.42 |
2021-06-30 | -7.28 | -0.21 | 63.19 |
2021-03-31 | -17.81 | 0.64 | 48.96 |
2020-12-31 | -28.34 | 1.50 | 34.74 |
2020-09-30 | -28.90 | 6.25 | 40.99 |
2020-06-30 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/e untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -9.16.
- p/libro untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 7.20.
- p/tbv untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 7.27.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | -9.16 | 7.20 | 7.27 |
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 | |||
2020-06-30 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.13.
- EBIT (3 tahun) / EV untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.10.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -0.13 | -0.10 |
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | 0.00 | -0.50 |
2022-06-30 | ||
2022-03-31 | 0.00 | -0.53 |
2021-12-31 | ||
2021-09-30 | 0.00 | -0.25 |
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | ||
2020-09-30 | ||
2020-06-30 |
Efektivitas Manajemen
- roa untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.49.
- roe untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.60.
- roic untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.71.
- croic untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah 0.21.
- ocroic untuk Mereo BioPharma Group plc - Depositary Receipt (Common Stock) pada 2025 Jun 30 adalah -0.50.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.49 | -0.60 | -0.71 | 0.21 | -0.50 |
2025-03-31 | -0.77 | -1.01 | -0.64 | 0.18 | -0.49 |
2024-12-31 | -0.68 | -0.90 | -0.57 | 0.23 | -0.38 |
2024-09-30 | -0.55 | -0.73 | -0.43 | 0.41 | -0.24 |
2024-06-30 | -0.30 | -0.51 | -0.49 | -0.21 | -0.37 |
2024-03-31 | -0.52 | -0.19 | -0.37 | ||
2023-12-31 | -0.30 | -0.42 | -0.46 | -0.38 | -0.42 |
2023-09-30 | -0.39 | -0.51 | -0.50 | ||
2023-06-30 | -0.32 | -0.49 | -0.37 | -0.49 | -0.47 |
2023-03-31 | -0.43 | -0.51 | -0.51 | ||
2022-12-31 | -0.15 | -0.21 | -0.33 | -0.45 | -0.46 |
2022-09-30 | -0.41 | ||||
2022-06-30 | 0.09 | 0.16 | -0.22 | -0.39 | -0.39 |
2022-03-31 | 0.00 | 0.00 | -0.04 | ||
2021-12-31 | -0.43 | 0.12 | 0.65 | -0.07 | |
2021-09-30 | 0.00 | -0.08 | |||
2021-06-30 | -0.25 | -1.11 | -0.27 | 0.53 | -0.07 |
2021-03-31 | -0.87 | -3.93 | -0.94 | 0.30 | -0.18 |
2020-12-31 | -1.89 | -4.06 | -55.19 | 2.40 | -9.56 |
2020-09-30 | -1.77 | -3.81 | -9.46 | 1.10 | -1.78 |
2020-06-30 | -1.34 | -2.43 | -2.82 | 0.56 | -0.58 |
Gross Margins
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | |||
2025-03-31 | 1.27 | -43.25 | -45.72 |
2024-12-31 | 1.27 | -45.32 | -38.07 |
2024-09-30 | 1.51 | -36.85 | -37.90 |
2024-06-30 | 0.71 | -2.63 | -2.56 |
2024-03-31 | 0.74 | -2.95 | -2.71 |
2023-12-31 | 0.74 | -3.66 | -4.44 |
2023-09-30 | 0.74 | -3.66 | -4.44 |
2023-06-30 | -3.66 | -4.44 | |
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | 0.51 | ||
2022-03-31 | -0.16 | 0.00 | |
2021-12-31 | 0.50 | 0.35 | -0.57 |
2021-09-30 | -0.19 | 0.00 | |
2021-06-30 | 0.50 | -0.74 | -0.58 |
2021-03-31 | 0.50 | -5.23 | -1.61 |
2020-12-31 | |||
2020-09-30 | |||
2020-06-30 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1719714 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |